| 王 磊,吴冠吉,王 军,刘海涛,马前锋.益心康泰胶囊联合倍他乐克治疗冠心病心绞痛效果及对临床症状、机体细胞因子的影响[J].现代生物医学进展英文版,2024,(14):2704-2708. |
| 益心康泰胶囊联合倍他乐克治疗冠心病心绞痛效果及对临床症状、机体细胞因子的影响 |
| The Effect of Yixin Kangtai Capsule Combined with Betaloc in the Treatment of Coronary Heart Disease Angina Pectoris and Its Impact on Clinical Symptoms and Body Cytokines |
| Received:February 08, 2024 Revised:February 28, 2024 |
| DOI：10.13241/j.cnki.pmb.2024.14.019 |
| 中文关键词: 益心康泰胶囊 倍他乐克 冠心病 心绞痛 临床症状 细胞因子 生存质量 |
| 英文关键词: Yixin Kangtai Capsules Betaloc Coronary heart disease Angina pectoris Clinical symptoms Cytokines Quality of Life |
| 基金项目:陕西省自然科学基础研究计划项目（2022-JM-581） |
|
| Hits: 14 |
| Download times: 13 |
| 中文摘要: |
| 摘要 目的：探讨益心康泰胶囊联合倍他乐克治疗冠心病心绞痛效果及对临床症状、机体细胞因子的影响。方法：选取2020年10月到2023年10月收治的80例冠心病心绞痛患者，分为观察组、对照组，各40例。对照组采取倍他乐克治疗，观察组采取益心康泰胶囊联合倍他乐克治疗，对比两组患者治疗前后心绞痛发作次数、持续时间及中医证候积分变化，中性粒细胞明胶酶相关载脂蛋白（NGAL）、心肌营养素1（CT-1）、白细胞介素-18（IL-18）、白三烯B4（LTB4）、组织内转化生长因子?茁结合蛋白（LTBP-2）相关机体细胞因子变化，血流变学指标变化，最后采取明尼苏达心力衰竭生活质量问卷（MLHFQ）评价两组患者生存质量。结果：治疗后：两组患者临床症状有所改善，且观察组较对照组改善幅度大（P＜0.05）；患者机体细胞因子水平降低，且观察组较对照组低（P＜0.05）；两组患者血小板聚集率、血浆黏度、全血低切、全血高切水平降低，且观察组低于对照组（P＜0.05）；两组患者MLHFQ评分升高，且观察组高于对照组（P＜0.05）。结论：对冠心病心绞痛患者使用益心康泰胶囊联合倍他乐克进行治疗，可减少心绞痛发作次数，缩短心绞痛持续时间，减轻患者临床症状，同时可改善患者机体细胞因子表达水平，降低血液黏度，提升患者生存质量。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the therapeutic effect of Yixin Kangtai Capsules combined with Betaloc in the treatment of coronary heart disease angina pectoris, as well as its impact on clinical symptoms and body cytokines. Methods: 80 CAD angina patients admitted from October 2020 to October 2023 were selected and divided into observation group and control group, 40 patients each. The Matched group received treatment with Betaloc, while the observation group received treatment with Yixin Kangtai Capsules combined with Betaloc. The number and duration of angina attacks, changes in traditional Chinese medicine syndrome scores, neutrophil gelatinase associated lipoprotein (NGAL), cardiotrophin-1 (CT-1), and interleukin-18 (IL-18) were compared between the two groups of patients before and Post-treatment Leukotriene B4 (LTB4), tissue transforming growth factor β Transforming growth factors within the organization β The changes in cytokines and hemorheological indicators related to the binding protein (LTBP-2) were evaluated, and the quality of life of the two groups of patients was evaluated using the Minnesota Heart Failure Quality of Life Questionnaire (MLHFQ). Results: Post-treatment: The clinical symptoms of the two groups improved, and the observation group improved greatly compared with the matched group(P<0.05); Post-treatment, The cytokine levels were reduced in both groups, and the observation group was lower than the matched group(P<0.05); Post-treatment, platelet aggregation rate, plasma viscosity, whole blood low shear, and whole blood high shear levels were significantly reduced in both groups of patients, and the observation group was lower than the matched group (P<0.05); Post-treatment , the MLHFQ scores of the two groups of patients increased, and the observation group was higher than the matched group (P<0.05). Conclusion: For patients with coronary heart disease and angina pectoris, Yixin Kangtai capsule combined with betalk can reduce the number of angina attacks, shorten the duration of angina pectoris, reduce the clinical symptoms of patients, improve the cytokine expression level of patients, reduce blood viscosity, and improve the quality of life of patients. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
